Regulatory Governance and the Evolution of Lean Regulators: Navigating the Complex Dynamics of Industry Relations in Pharmaceutical Oversight

 Corresponding author: Mohamed Khalil TAMIM Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0. Regulatory Governance and the Evolution of Lean Regulators: Navigating the Complex Dynamics of Industry Relations in Pharmaceutical Oversight Mohamed Khalil TAMIM * Department of Quality and Regulatory Affairs, Alcon Pharmaceuticals Ltd. Rue Louis D'Affry 6 Fribourg, 1700, Switzerland. World Journal of Biology Pharmacy and Health Sciences, 2025, 24(01), 345-352 Publication history: Received on 14 September 2025; revised on 19 October 2025; accepted on 22 October 2025 Article DOI: https://doi.org/10.30574/wjbphs.2025.24.1.0919 Abstract The pharmaceutical regulatory landscape has undergone substantial transformation over the past three decades, with regulatory authorities increasingly adopting “lean” operational models in response to resource constraints, scientific complexity, and demands for expedited market access. This perspective article examines the governance frameworks underpinning major regulatory bodies, particularly the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA), and analyzes how lean regulatory approaches have fundamentally impacted the regulator-industry relationship. We explore the paradox of maintaining regulatory independence while fostering collaborative paradigms, the implications of resource-constrained oversight on public health protection, and the emerging challenges posed by adaptive licensing, accelerated approval pathways, and industry-funded regulatory activities. Through critical analysis of current governance models, we identify key tensions between efficiency imperatives and traditional regulatory safeguards, proposing a framework for sustainable regulatory excellence that balances innovation facilitation with robust public health protection. This perspective contributes to ongoing discourse on regulatory science governance and offers insights for policy development in an era of unprecedented biomedical innovation. Keywords: Regulatory Governance; Lean Regulation; Pharmaceutical Oversight; Industry Relations; Regulatory Science; Adaptive Licensing 1. Introduction Pharmaceutical regulation exists at a critical nexus between public health protection, scientific innovation, and commercial imperatives. Regulatory authorities serve as gatekeepers, ensuring that medicinal products meet stringent standards of safety, efficacy, and quality before reaching patients [1]. However, the operational paradigms governing these institutions have evolved considerably, driven by escalating scientific complexity, constrained public resources, and intensifying demands for rapid access to novel therapeutics [2,5]. The concept of “lean regulation” has emerged as both a pragmatic response to resource limitations and a philosophical shift toward efficiency-oriented governance. Drawing from lean management principles developed in manufacturing sectors, lean regulatory models emphasize streamlined processes, elimination of redundancies, risk-based oversight, and enhanced regulator-industry collaboration [6,7]. While proponents argue that such approaches accelerate innovation without compromising safety, critics contend that lean models may inadvertently erode regulatory independence and diminish the robustness of oversight mechanisms [4,6]. This perspective examines the governance structures of major pharmaceutical regulators, with particular focus on the FDA and MHRA, analyzing how organizational mandates, funding mechanisms, and stakeholder relationships shape World Journal of Biology Pharmacy and Health Sciences, 2025, 24(01), 345-352 346 regulatory decisions. We critically evaluate the implications of lean regulatory practices for industry relations, exploring whether current frameworks adequately balance competing objectives of efficiency, rigor, and public trust. 2. The Architecture of Regulatory Governance 2.1. Foundational Principles and Institutional Mandates Pharmaceutical regulatory authorities operate within complex governance ecosystems defined by legislative mandates, political accountability structures, and resource allocation mechanisms [1,13]. The FDA, established through the Food, Drug, and Cosmetic Act and subsequent amendments, functions as a science-based regulatory agency within the US Department of Health and Human Services. Its mandate encompasses pre-market evaluation, post-market surveillance, and enforcement actions across multiple product categories. The MHRA, operating under the Human Medicines Regulations and guided by UK and international frameworks, similarly combines pre-authorization assessment with pharmacovigilance responsibilities [22,29]. Following Brexit, the MHRA has gained regulatory autonomy, creating opportunities for distinctive governance approaches while navigating challenges of maintaining international regulatory alignment. Both agencies exemplify science-based regulatory models, wherein decisions theoretically derive from objective evaluation of clinical and preclinical evidence [1]. However, the operationalization of scientific judgment within regulatory frameworks involves discretionary elements, stakeholder input mechanisms, and policy considerations that transcend pure empiricism. 2.2. Funding Models and Structural Dependencies A defining feature of contemporary regulatory governance is the prevalence of industry-funded user fee systems [4,14]. The FDA’s Prescription Drug User Fee Act (PDUFA), enacted in 1992 and repeatedly reauthorized, represents a watershed in regulatory financing. Under PDUFA, pharmaceutical companies pay substantial fees for new drug application reviews, with these funds designated for accelerating evaluation timelines. By fiscal year 2023, user fees constituted approximately 65% of the FDA’s human drugs program budget [14]. The MHRA similarly derives substantial revenue from industry fees, operating as a revenue-generating entity within UK government structures [19]. This funding model creates inherent tensions: while user fees enable enhanced regulatory capacity, they also establish financial dependencies that may influence institutional priorities and decision-making cultures [5,6]. The regulatory economics literature has extensively debated whether industry funding compromises regulatory independence [11,12]. Proponents argue that fee structures incorporate safeguards, including Congressional oversight (FDA) and parliamentary accountability (MHRA), and that fees support rather than supplant regulatory rigor. However, empirical analyses suggest correlations between industry funding and expedited approvals, raising questions about whether financial arrangements subtly shift risk-benefit calculi toward industry interests [4,14]. World Journal of Biology Pharmacy and Health Sciences, 2025, 24(01), 345-352 347 Figure 1 Growth of Industry-Funded User Fees in FDA Human Drugs Program (2010–2023) 3. Lean Regulation: Concepts, Implementation, and Rationales 3.1. Defining Lean Regulatory Models 3.1.1. Lean regulation encompasses multiple dimensions Process Optimization: Streamlining review procedures through standardized templates, enhanced pre-submission engagement, and parallel rather than sequential evaluation phases. Risk-Based Resource Allocation: Concentrating regulatory scrutiny on products presenting higher risk profiles while implementing abbreviated pathways for lower-risk categories or therapeutics addressing unmet medical needs [19]. Reliance and Work-Sharing: Leveraging assessments conducted by other trusted regulatory authorities to reduce duplicative evaluation efforts [22]. Adaptive and Iterative Approval: Employing conditional authorizations, accelerated pathways, and real-world evidence integration to enable earlier market access with post-market data collection commitments [7,26]. Enhanced Industry Collaboration: Establishing formal mechanisms for pre-application consultations, scientific advice procedures, and collaborative problem-solving during development and review phases [13]. Table 1 Comparative Features of Lean Regulatory Models: FDA vs MHRA Feature FDA MHRA Funding Source 65% industry-funded (PDUFA) Substantial industry fees Expedited Pathways Accelerated Approval, Breakthrough Therapy MHRA Early Access to Medicines Scheme (EAMS), Innovation Office Collaboration Mechanisms Scientific advice, pre-submission consultations Scientific advice, early access schemes 3.2. Drivers of Lean Regulatory Adoption Multiple factors have propelled regulatory agencies toward lean operational models [2,6,15]: World Journal of Biology Pharmacy and Health Sciences, 2025, 24(01), 345-352 348 • Fiscal Constraints: Government budget limitations have necessitated more efficient resource utilization and increased reliance on industry funding [5,14]. • Scientific Complexity: Advances in biologics, gene therapies, personalized medicine, and biomarker-driven development have outpaced traditional regulatory frameworks, requiring adaptive approaches [15,26]. • Political and Public Pressure: Patient advocacy groups, particularly in oncology and rare diseases, have demanded accelerated access to experimental therapeutics, creating political imperatives for expedited pathways [2,16]. Globalization: Pharmaceutical development has become increasingly multinational, with companies seeking regulatory efficiencies across jurisdictions, prompting harmonization initiatives [22]. • Innovation Facilitation Mandates: Modern regulatory philosophy increasingly emphasizes enabling innovation alongside traditional safety-focused missions, reflected in programs like FDA’s Breakthrough Therapy designation and MHRA’s Innovation Office [2,16]. 4. Regulator-Industry Dynamics in the Lean Era 4.1. The Collaborative Paradigm Shift Traditional adversarial characterizations of regulator-industry relationships have given way to collaborative frameworks [1,13]. Both FDA and MHRA have institutionalized extensive pre-submission consultation mechanisms, scientific advice procedures, and ongoing dialogue throughout product development. These interactions, while potentially beneficial for clarifying regulatory expectations and resolving scientific uncertainties, also create opportunities for industry influence on regulatory standards [6,20]. The pharmaceutical industry invests substantially in maintaining productive regulatory relationships, employing regulatory affairs professionals, engaging consultants with former regulatory experience, and participating in advisory committee processes [18]. This professionalization of regulatory engagement, while enhancing communication quality, may also enable sophisticated strategic influence. 4.2. Accelerated Pathways and Conditional Approvals Lean regulatory models have proliferated expedited approval mechanisms [2,16]: • FDA Accelerated Approval: Permits authorization based on surrogate endpoints reasonably likely to predict clinical benefit, with confirmatory trials required post-approval [8,9]. • FDA Breakthrough Therapy Designation: Provides intensive guidance and accelerated review for therapeutics showing substantial preliminary evidence of improvement over existing options [2,16]. • MHRA Early Access to Medicines Scheme (EAMS): Facilitates access to promising therapeutics prior to full authorization in life-threatening conditions. • EMA PRIME Scheme: Enhances support for medicines targeting unmet needs, with implications for MHRAindustry interactions given historical regulatory alignment [17]. While these pathways serve important public health objectives, they shift risk-benefit assessments toward accepting greater uncertainty at authorization, transferring evidence generation to post-market phases [3,8]. This approach assumes robust post-market surveillance and enforcement mechanisms—assumptions that warrant scrutiny given documented challenges in ensuring timely completion of confirmatory studies [10]. 4.3. The Post-Market Evidence Paradox Lean regulatory models increasingly rely on post-market evidence generation to confirm pre-approval hypotheses [8,10]. However, regulatory authorities face substantial challenges in enforcing post-market commitments. Studies have documented prolonged delays in confirmatory trial completion, with some products remaining marketed for years without confirmation of clinical benefit [10]. The FDA’s ability to withdraw accelerated approvals has been questioned, with criticisms that commercial entanglement and established prescribing patterns create barriers to market removal even when confirmatory evidence disappoints [9]. This dynamic illustrates a fundamental tension in lean regulation: efficiency gains during authorization may create downstream accountability gaps that ultimately compromise public health protection [3,10]. World Journal of Biology Pharmacy and Health Sciences, 2025, 24(01), 345-352 349 5. Governance Challenges and Systemic Tensions 5.1. Independence and Institutional Capture Regulatory theory posits risks of “cognitive capture,” wherein regulators unconsciously adopt industry perspectives through sustained professional interactions, and “financial capture,” wherein funding dependencies influence institutional priorities [11,12]. While overt corruption remains rare in pharmaceutical regulation, subtler forms of influence merit consideration [6,20]: Revolving Door Dynamics: Movement of personnel between regulatory agencies and pharmaceutical companies creates networks that may facilitate informal influence channels, though these relationships also transfer valuable expertise [18]. Stakeholder Consultation Asymmetries: Industry possesses resources to engage extensively in regulatory consultations, potentially drowning out other stakeholder voices and shaping regulatory frameworks toward commercial interests [21,28]. Cultural Alignment: Sustained collaboration may foster institutional cultures that prioritize partnership over critical oversight, with regulatory success increasingly measured by industry satisfaction alongside public health metrics [1,6]. 5.2. Transparency and Accountability Deficits Lean regulatory models often involve extensive confidential interactions between regulators and companies [23]. While protecting proprietary information serves legitimate purposes, opacity limits external accountability. Civil society organizations have criticized insufficient disclosure of regulatory decision-making rationales, clinical trial data, and safety signal assessments [23,25]. Both FDA and MHRA have implemented transparency initiatives, including clinical trial results databases and summary review documents [23]. However, substantial information asymmetries persist, limiting independent evaluation of regulatory decisions and potentially enabling suboptimal outcomes to escape scrutiny [6,20]. 5.3. Global Regulatory Fragmentation and Harmonization Challenges While lean regulation emphasizes international collaboration and reliance mechanisms, substantive regulatory divergence persists [22]. Brexit has complicated UK-EU regulatory relationships, with MHRA establishing independent pathways while seeking continued collaboration. Differences in approval standards, post-market requirements, and pharmacovigilance expectations create compliance complexities that may disadvantage smaller companies and certain therapeutic areas [29]. Initiatives like the International Council for Harmonization (ICH) promote convergence, yet fundamental differences in regulatory philosophy—particularly regarding acceptable evidence standards and risk tolerance—remain [22]. Lean approaches risk exacerbating rather than resolving these tensions if efficiency measures are implemented unilaterally without ensuring regulatory robustness. 6. Toward Sustainable Regulatory Excellence 6.1. Principles for Balanced Governance Effective pharmaceutical regulation in resource-constrained environments requires governance frameworks that [1,25]: • Preserve Core Independence: Funding models should incorporate structural safeguards preventing industry influence on regulatory standards, including diversified funding sources and transparent fee allocation mechanisms [12,14]. • Enhance Evidence Standards: Accelerated pathways must maintain rigorous efficacy evidence requirements, with surrogate endpoints validated for clinical relevance and confirmatory trial commitments strictly enforced [3,8,9]. World Journal of Biology Pharmacy and Health Sciences, 2025, 24(01), 345-352 350 Strengthen Post-Market Systems: Robust pharmacovigilance, real-world evidence infrastructure, and enforcement capabilities must accompany any expansion of conditional or accelerated authorizations [10,29]. • Promote Transparency: Maximizing disclosure of regulatory decision-making processes, clinical trial data, and safety information enables external accountability and public trust [23,25]. • Balance Stakeholder Input: Regulatory consultation mechanisms should ensure meaningful participation from patients, healthcare providers, payers, and civil society alongside industry engagement [27]. • Invest in Regulatory Science: Public investment in regulatory science infrastructure, methodological development, and workforce expertise is essential for maintaining technical capabilities independent of industry resources [15,24]. 6.2. Alternative Funding Models Several alternative or complementary funding approaches merit consideration [5,14]: • Enhanced Public Appropriations: Direct government funding could reduce industry dependency, though securing sustained budgetary commitments presents political challenges. • Outcome-Based Fees: Linking fee structures to post-market performance or value realization rather than application volume might better align incentives [26,27]. • Market-Entry Levies: Broader pharmaceutical industry contributions rather than application-specific fees could reduce transactional dependencies. • International Cost-Sharing: Collaborative regulatory initiatives with shared funding might achieve efficiencies while distributing capture risks [22,24]. 6.3. Technological Innovation in Regulatory Practice Emerging technologies offer opportunities for enhancing regulatory efficiency without compromising rigor [26]: • Artificial Intelligence and Machine Learning: Automated safety signal detection, literature surveillance, and data analysis tools could augment regulatory capacity. • Real-World Data Platforms: Interoperable health data infrastructure enables more robust post-market evidence generation and safety monitoring [7,26]. • Advanced Analytics: Computational modeling and simulation approaches may enhance evidence evaluation and regulatory decision-making. However, technological adoption requires careful governance to ensure algorithms serve public health objectives rather than introducing new biases or opacity [23]. 7. Conclusion The evolution toward lean regulatory models reflects legitimate pressures for efficiency and innovation facilitation in resource-constrained environments. However, this transformation has fundamentally altered regulator-industry dynamics, creating governance challenges that demand ongoing scrutiny and adaptation. The pharmaceutical regulatory enterprise must navigate inherent tensions between operational efficiency and comprehensive oversight, collaborative engagement and institutional independence, accelerated access and robust evidence standards. Current governance frameworks, particularly in mature regulatory systems like FDA and MHRA, have incorporated important safeguards. Yet the sustainability of lean regulation ultimately depends on continuous vigilance against regulatory capture, substantial investment in post-market surveillance capabilities, maximal transparency in decisionmaking processes, and periodic reassessment of whether efficiency gains justify potential compromises to public health protection. The coming decades will test whether lean regulatory models can deliver on their promise of maintaining gold-standard safety and efficacy evaluation while adapting to scientific advancement and resource realities. Success will require not only technical and procedural innovation but also unwavering commitment to regulatory independence, evidencebased decision-making, and the primacy of public health over competing interests. Future research should examine empirical relationships between specific lean regulatory practices and patient outcomes, explore comparative governance models across jurisdictions, and evaluate the long-term sustainability of industry-funded regulatory systems. As pharmaceutical innovation continues its remarkable trajectory, ensuring that World Journal of Biology Pharmacy and Health Sciences, 2025, 24(01), 345-352 351 regulatory governance evolves appropriately—preserving essential protections while enabling beneficial therapies— remains among the most critical challenges in contemporary health policy. Compliance with ethical standards Disclosure of conflict of interest This perspective was developed independently and does not represent the views, opinions, or interests of Alcon or any of its subsidiaries or affiliated companies. This work was conducted in the author's personal capacity without institutional resources, funding, or support from Alcon. References [1] Carpenter D. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Princeton, NJ: Princeton University Press; 2010. [2] Darrow JJ, Avorn J, Kesselheim AS. New FDA breakthrough-drug category—implications for patients. N Engl J Med. 2014;370(13):1252-1258. [3] Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA. 2014;311(4):368-377. [4] Carpenter D, Zucker EJ, Avorn J. Drug-review deadlines and safety problems. N Engl J Med. 2008;358(13):13541361. [5] Lexchin J. Private profits versus public policy: the pharmaceutical industry and the Canadian state. University of Toronto Press; 2016. [6] Abraham J, Davis C. Unhealthy Pharmaceutical Regulation: Innovation, Politics and Promissory Science. Basingstoke: Palgrave Macmillan; 2013. [7] Eichler HG, Oye K, Baird LG, et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther. 2012;91(3):426-437. [8] Naci H, Smalley KR, Kesselheim AS. Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration. JAMA. 2017;318(7):626-636. [9] Gyawali B, Hey SP, Kesselheim AS. Assessment of the clinical benefit of cancer drugs receiving accelerated approval. JAMA Intern Med. 2019;179(7):906-913. [10] Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. N Engl J Med. 2017;377(12):1114-1117. [11] Peltzman S. An evaluation of consumer protection legislation: the 1962 drug amendments. J Polit Econ. 1973;81(5):1049-1091. [12] Stigler GJ. The theory of economic regulation. Bell J Econ Manag Sci. 1971;2(1):3-21. [13] Sifuentes, M. M., Giuffrida, A. Drug Review Differences across the United States and the European Union. Pharmaceutical Regulatory Affairs: Open Access, 2015; 4(4). DOI: 10.4172/2167-7689.1000e156 [14] Olson MK. Managing delegation in the FDA: reducing delay in new-drug review. J Health Polit Policy Law. 2004;29(3):397-429. [15] Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012;345: e4348. [16] Kesselheim AS, Wang B, Franklin JM, Darrow JJ. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ. 2015;351:h4633. [17] Mossialos, E., Permanand, G., Baeten, R., & Hervey, T. (Eds.). Health Systems Governance in Europe: The Role of European Union Law and Policy. Cambridge University Press. 2010. [18] Lurie P, Almeida CM, Stine N, Stine AR, Wolfe SM. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings. JAMA. 2006;295(16):1921-1928. World Journal of Biology Pharmacy and Health Sciences, 2025, 24(01), 345-352 352 [19] Beaussier AL, Demeritt D, Griffiths A, Rothstein H. Accounting for failure: risk-based regulation and the problems of ensuring healthcare quality in the NHS. Health Risk Soc. 2016;18(3-4):205-224. [20] Davis C, Abraham J. Is there a cure for corporate crime in the drug industry? BMJ. 2013;346:f755. [21] Lexchin J. Sponsorship bias in clinical research. Int J Risk Saf Med. 2012;24(4):233-242. [22] Vogel D. The globalization of pharmaceutical regulation. Governance. 1998;11(1):1-22. [23] Gøtzsche PC, Jørgensen AW. Opening up data at the European Medicines Agency. BMJ. 2011;342:d2686. [24] Pezzola, A., Sweet, C.M. Global pharmaceutical regulation: the challenge of integration for developing states. Global Health; 2016; 12, 85. https://doi.org/10.1186/s12992-016-0208-2 [25] Garattini S, Bertele V. How can we regulate medicines better? BMJ. 2007;335(7624):803-805. [26] Eichler HG, Bloechl-Daum B, Bauer P, et al. Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nat Rev Drug Discov. 2010;9(4):277-291. [27] Sorenson C, Drummond M, Kanavos P. Ensuring value for money in health care: the role of health technology assessment in the European Union. European Observatory on Health Systems and Policies; 2008. [28] Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials. 2008;29(2):109-113 [29] Wiktorowicz ME, Lexchin J, Moscou K. Pharmacovigilance in Europe and North America: divergent approaches. Soc Sci Med. 2012;75(1):165-170.